New hope for rare lymphomas: drug that blocks JAK protein under study

NCT ID NCT02974647

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug ruxolitinib in people with T or NK cell lymphoma that has come back or not responded to prior treatment. Ruxolitinib works by blocking a protein called JAK, which helps these cancer cells survive. The goal is to see if the drug can shrink tumors or control the disease. About 83 adults will take part in this Phase 2 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat T or NK cell lymphomas, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is an early Phase 2 trial with only 83 participants, so results may not apply to everyone. The drug may not work for all types of lymphoma, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma lymphoma Recurrence T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

Dana Farber Cancer Institute
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02115, United States
Memorial Sloan Kettering Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States
Northwestern Medicine (Data collection and specimen analysis)
ACTIVE_NOT_RECRUITING

Chicago, Illinois, 60611, United States
University of Miami
ACTIVE_NOT_RECRUITING

Miami, Florida, United States
Weill Cornell Medical College
ACTIVE_NOT_RECRUITING

New York, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.